Company news

Palvella Therapeutics, Inc. news

Latest news releases, newest first. Pick a year for every news release, call and deck from that year.

View company

Pieris Pharmaceuticals Announces Dosing of First Patient in Phase 2 Gastric Cancer Trial of 4–1BB/HER2 Bispecific Cinrebafusp Alfa

January 13, 2022

Pieris Pharmaceuticals Announces Successful Completion of Safety Milestone and Initiation of Efficacy Portion of Phase 2a Trial of PRS-060/AZD1402

January 2, 2022

Pieris Pharmaceuticals To Participate In Upcoming Investor Conferences

November 10, 2021

Pieris Pharmaceuticals and Servier Announce Dosing of First Patient in Phase 1/2 Trial of 4-1BB/PD-L1 Bispecific PRS-344/S095012

November 7, 2021

Pieris Pharmaceuticals Reports Third Quarter 2021 Financial Results and Provides Corporate Update

November 1, 2021

Pieris Pharmaceuticals To Host Third Quarter 2021 Investor Call and Provide Corporate Update on November 2, 2021

October 25, 2021

Pieris Pharmaceuticals Announces Appointments of Chief Financial Officer and Chief Business Officer

October 5, 2021

Pieris Pharmaceuticals to Participate in Upcoming Investor Conferences

September 8, 2021

Pieris Pharmaceuticals Announces PRS-220 Presentation at ERS Highlighting Preclinical Data for CTGF Inhibitor

August 23, 2021

Pieris Pharmaceuticals Reports Second Quarter 2021 Financial Results and Provides Corporate Update

August 3, 2021

Pieris Pharmaceuticals Strengthens Executive R&D Leadership Team

August 2, 2021

Pieris Pharmaceuticals to Host Second Quarter 2021 Investor Call and Provide Corporate Update on August 4, 2021

July 27, 2021

Pieris Pharmaceuticals Announces Inhaled CTGF Inhibitor PRS-220 for Idiopathic Pulmonary Fibrosis and 17 Million Dollar Grant From Bavarian Government To Accelerate Program Development for Post-COVID-19 Pulmonary Fibrosis

June 24, 2021

Pieris Pharmaceuticals Receives Orphan Drug Designation for Cinrebafusp Alfa for the Treatment of Gastric Cancer

June 23, 2021

Pieris Pharmaceuticals Announces Respiratory and Ophthalmology Collaboration with Genentech

May 24, 2021

Pieris Pharmaceuticals to Present at the Jefferies 2021 Virtual Healthcare Conference

May 19, 2021

Pieris Pharmaceuticals Reports First Quarter 2021 Financial Results and Provides Corporate Update

May 16, 2021

Pieris Pharmaceuticals to Host First Quarter 2021 Investor Call and Provide Corporate Update on May 17, 2021

May 9, 2021

Pieris Pharmaceuticals and Boston Pharmaceuticals Enter into an Exclusive Worldwide Product License for PRS-342, a 4-1BB/GPC3 Immuno-Oncology Bispecific

April 25, 2021

Pieris Pharmaceuticals Presents Updated Phase 1 Monotherapy Data for 4-1BB/HER2 Bispecific Cinrebafusp Alfa and Preclinical Data for 4-1BB/PD-L1 Bispecific PRS-344/S095012 at 2021 AACR Annual Meeting

April 9, 2021

Pieris Pharmaceuticals Reports Full-Year 2020 Financial Results and Provides Corporate Update

March 29, 2021

Pieris Pharmaceuticals to Host Full-Year 2020 Investor Call and Provide Corporate Update on March 30, 2021

March 22, 2021

← Newer news releases

Calls

The 5 newest of 8 calls. Every call is listed under its year.

Decks

The 5 newest of 24 decks. Every deck is listed under its year.